Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothi
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:8/29/2014)... The new review that can be read on DailyGossip.org indicates ... will permanently eliminate the symptoms of this disease. , ... cure in as fast as 30 to 60 days. However, ... week. , The Tinnitus Miracle review indicates that this ... loss, pain in the ear and dizziness. Read the full ...
(Date:8/29/2014)... Cosmetic Town is a cosmetic ... plastic surgeons with prospective patients. The site showcases ... techniques in plastic and reconstructive surgery. Articles are ... reliable information for general readers, who are looking ... Town began featuring renowned cosmetic specialists from Los ...
(Date:8/29/2014)... The Nasal Polyps Treatment Miracle ... new program is actually based on some powerful ... by a former nasal polyps sufferer, who in ... problem. Manuel Richards suffered from nasal polyps for ... , Learn more about Manuel Richards' new book ...
(Date:8/29/2014)... The Department of Health and Human ... code CMS–0052–P) today allowing healthcare providers to attest for ... EHR Technology (CEHRT) or a combination of the 2011 ... not been able to fully implement 2014 Edition CEHRT ... continue to use 2011 Edition CEHRT, or a combination ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2
... of a ban on Coke and Pepsi by the Kerala Government, ... putting forth a proposal to stop the sale// and production of ... ,Top brass in the companies are very unhappy over these ... private company which is not in sync with the reports ...
... Minister Tony Abbott yesterday accused the commonwealth of bankrolling ... public money was spent.// ,He attacked ... should be able to fund public hospitals using the ... ,State health ministers, outraged at Mr Abbott's position accused ...
... too much take-away food and pile on weight will soon ... ,The National Heart Foundation's tick is a label that ... and will soon make its appearance at restaurants, take-away outlets ... by analyst BIS Shrapnel who showed that 70 percent of ...
... for one to undergo an operation.// ,A team ... analysed the outcomes of over 90,000 operations carried out at ... time to have an operation, as they had found that ... published their study in the journal Quality and Safety in ...
... eating raw shellfish have made the U.S. Food and ... raw shellfish. Reports coming// in show that oysters and ... sick across the country. ,Till date there have been ... gastroenteritis after eating raw shellfish. The illness is caused ...
... condition that affects children as well as adults. A ... alleviate// symptoms and bring down the inflammation associated with ... 10 issue of the New England Journal of Medicine. ... the National Institute of Arthritis and Musculoskeletal and Skin ...
Cached Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Heart Tick for Fast Foods in Australia 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
... Skin Staple Remover is a plastic ... is packaged 12 units per box ... staples. The device works by slipping ... under the staple to be removed. ...
... place single staples to close surgical ... stainless steel; the staplers are not ... skin staplers to meet your needs., ... for routine skin closure in a ...
... is a full-feature skin stapler with a ... has improved visibility over existing fixed-head skin ... for easier staple placement., ,This Skin ... instrument designed to deliver rectangular, stainless steel ...
... Linear Staplers are available with either a ... instrument (non-reloadable). Each instrument contains 19 staples ... ,Benefits include: , Small profile stapling head ... , Articulating head rotates up to 80deg; ...
Medicine Products: